Aurora Cannabis (ACB) set for TD Cowen event, completes Bevo deal
Rhea-AI Filing Summary
Aurora Cannabis Inc. filed a report highlighting two main updates. The company will participate in TD Cowen's 46th Annual Health Care Conference in Boston, where CFO Simona King will join a fireside chat and investor meetings on March 2, 2026.
Aurora also announced it has completed its previously announced transaction with Bevo Agtech Inc., referred to as the Bevo Transaction. Further details of this transaction are available in the company’s February 4, 2026 press release on SEDAR+.
Positive
- None.
Negative
- None.
FAQ
What did Aurora Cannabis (ACB) disclose in its latest Form 6-K?
When will Aurora Cannabis (ACB) appear at the TD Cowen 46th Annual Health Care Conference?
Who will represent Aurora Cannabis (ACB) at the TD Cowen health care conference?
What is the Bevo Transaction completed by Aurora Cannabis (ACB)?
How can investors access Aurora Cannabis (ACB) TD Cowen conference webcast and replay?
What areas will Aurora Cannabis (ACB) discuss at the TD Cowen conference?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF
FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2026
Commission File No. 001-38691
AURORA
CANNABIS INC.
(Translation of registrant's name into English)
2207 90B St. SW
Edmonton, Alberta T6X 1V8
Canada
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
Form 20-F ☐ Form 40-F ☒
SUBMITTED HEREWITH
| Exhibits | Description | |
| 99.1 | News release dated February 17, 2026 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
AURORA CANNABIS INC.
/s/ Miguel Martin
Miguel Martin
Chief Executive Officer
Date: February 17, 2026
Exhibit 99.1
Aurora to Participate in the TD Cowen 46th Annual Health Care Conference
NASDAQ | TSX: ACB
Canada's Largest Global Medical Cannabis Company to Discuss Growth Strategy, Key Trends and Market Opportunities
EDMONTON, AB, Feb. 17, 2026 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, will participate in TD Cowen's 46th Annual Health Care Conference in Boston, MA. Simona King, Chief Financial Officer at Aurora, will take part in a fireside chat and one-on-one meetings with investors on March 2, 2026.
Aurora's CFO, Simona King will participate in TD Cowen's Annual Health Care Conference on March 2. (CNW Group/Aurora Cannabis Inc.)
Conference Details
DATE: Monday, March 2, 2026
TIME: 11:10am Eastern Time | 9:10am Mountain Time
WEBCAST: Click Here
The fireside chat will be hosted by Derek Lessard, VP of Equity Research at TD Cowen. The discussion will explore Aurora's international leadership, shifts reshaping the global medical cannabis landscape, advancements in Canadian manufacturing excellence, and the broader market forces influencing the industry's growth.
To listen to the live audio webcast, please register using the weblink above, which has also been posted to the Company's "Investor Info" section at https://www.auroramj.com/investors/ under "Events". A replay of the presentation will be available using the same link for approximately 90 days.
Further, the Company announces that it has completed the transaction with Bevo Agtech Inc. ("Bevo"), previously announced on February 4, 2026 (the "Bevo Transaction"). Full details of the Bevo Transaction can be found in the February 4, 2026 press release located under the Company's profile at www.sedarplus.ca.
About Aurora
Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance, and a deep commitment to patient care. Aurora serves both medical and consumer markets across Canada, Europe, Australia, and New Zealand, with a strategic focus on high-margin opportunities and a medical-first approach. Aurora's portfolio of trusted, leading brands includes Aurora®, MedReleaf®, Pedanios®, IndiMed™, San Raf®, Tasty's® and Whistler Medical Marijuana Co.®. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis™.
Learn more at www.auroramj.com and follow us on X and LinkedIn.
Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".
Forward Looking Information
This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the Company's upcoming participation at the TD Cowen 46th Annual Health Care Conference, as well as those related to the Company's global medical cannabis market leadership.
These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goods imported from Canada into the United States; the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 17, 2025 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-to-participate-in-the-td-cowen-46th-annual-health-care-conference-302691035.html
SOURCE Aurora Cannabis Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/February2026/17/c0605.html
%CIK: 0001683541
For further information: For Media: Michelle Lefler | VP, Communications & PR | media@auroramj.com; For Investors: ICR, Inc. | aurora@icrinc.com
CO: Aurora Cannabis Inc.
CNW 18:39e 17-FEB-26